Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us

Santosh Kumar, Michael Y. Sherman

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex and preventing the re-ligation of the DNA strand, leading to the formation of lethal DNA breaks. Following the initial response to irinotecan, secondary resistance is acquired relatively rapidly, compromising its efficacy. There are several mechanisms contributing to the resistance, which affect the irinotecan metabolism or the target protein. In addition, we have demonstrated a major resistance mechanism associated with the elimination of hundreds of thousands of Top1 binding sites on DNA that can arise from the repair of prior Top1-dependent DNA cleavages. Here, we outline the major mechanisms of irinotecan resistance and highlight recent advancements in the field. We discuss the impact of resistance mechanisms on clinical outcomes and the potential strategies to overcome resistance to irinotecan. The elucidation of the underlying mechanisms of irinotecan resistance can provide valuable insights for the development of effective therapeutic strategies.

Original languageEnglish
Article number7233
JournalInternational Journal of Molecular Sciences
Volume24
Issue number8
DOIs
StatePublished - Apr 2023

Keywords

  • DNA damage response
  • DNA repair
  • chemotherapy
  • dose escalation
  • drug resistance
  • irinotecan
  • topoisomerase I

Fingerprint

Dive into the research topics of 'Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us'. Together they form a unique fingerprint.

Cite this